These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

726 related items for PubMed ID: 27461244

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Silencing of long noncoding RNA LEF1-AS1 prevents the progression of hepatocellular carcinoma via the crosstalk with microRNA-136-5p/WNK1.
    Dong H, Jian P, Yu M, Wang L.
    J Cell Physiol; 2020 Oct; 235(10):6548-6562. PubMed ID: 32068261
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Endoplasmic reticulum resident oxidase ERO1-Lalpha promotes hepatocellular carcinoma metastasis and angiogenesis through the S1PR1/STAT3/VEGF-A pathway.
    Yang S, Yang C, Yu F, Ding W, Hu Y, Cheng F, Zhang F, Guan B, Wang X, Lu L, Rao J.
    Cell Death Dis; 2018 Oct 30; 9(11):1105. PubMed ID: 30377291
    [Abstract] [Full Text] [Related]

  • 6. Fatty acid binding protein 5 promotes tumor angiogenesis and activates the IL6/STAT3/VEGFA pathway in hepatocellular carcinoma.
    Pan L, Xiao H, Liao R, Chen Q, Peng C, Zhang Y, Mu T, Wu Z.
    Biomed Pharmacother; 2018 Oct 30; 106():68-76. PubMed ID: 29957468
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
    Yu M, Xue H, Wang Y, Shen Q, Jiang Q, Zhang X, Li K, Jia M, Jia J, Xu J, Tian Y.
    Int J Oncol; 2017 Mar 30; 50(3):975-983. PubMed ID: 28098858
    [Abstract] [Full Text] [Related]

  • 10. Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling.
    Liu P, Atkinson SJ, Akbareian SE, Zhou Z, Munsterberg A, Robinson SD, Bao Y.
    Sci Rep; 2017 Oct 04; 7(1):12651. PubMed ID: 28978924
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/β-catenin signaling through targeting BCL9.
    Yang C, Xu Y, Cheng F, Hu Y, Yang S, Rao J, Wang X.
    Cell Death Dis; 2017 Aug 17; 8(8):e2999. PubMed ID: 28817119
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma.
    Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC, Huang CH, Lee YS, Yen TC, Hsieh SY.
    J Hepatol; 2012 Sep 17; 57(3):584-91. PubMed ID: 22613005
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. miR-139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF-4 pathway.
    Gu W, Li X, Wang J.
    Oncol Rep; 2014 Jan 17; 31(1):397-404. PubMed ID: 24190507
    [Abstract] [Full Text] [Related]

  • 18. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.
    Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, Ye QH, Qin LX.
    Hepatology; 2014 May 17; 59(5):1874-85. PubMed ID: 24259426
    [Abstract] [Full Text] [Related]

  • 19. Down-regulation of microRNA-338-3p promoted angiogenesis in hepatocellular carcinoma.
    Zhang T, Liu W, Zeng XC, Jiang N, Fu BS, Guo Y, Yi HM, Li H, Zhang Q, Chen WJ, Chen GH.
    Biomed Pharmacother; 2016 Dec 17; 84():583-591. PubMed ID: 27694002
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.